Optimization of Therapy for Severe Aplastic Anemia Based on Clinical, Biologic, and Treatment Response Parameters: Conclusions of an International Working.

Slides:

Advertisements

Similar presentations

Stephanie J. Lee, Loretta A. Williams

Advertisements

Sirolimus in Combination with Cyclosporine or Tacrolimus Plus Methotrexate for Prevention of Graft-versus-Host Disease following Hematopoietic Cell Transplantation.

Megan Othus, Frederick R. Appelbaum, Stephen H. Petersdorf, Kenneth J

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui

Alternative Allogeneic Donor Sources for Transplantation for Childhood Diseases: Unrelated Cord Blood and Haploidentical Family Donors Mitchell S. Cairo,

The Outcome of Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Remission Who Were.

Vaccination of Children following Allogeneic Stem Cell Transplantation

Changing Trends of Unrelated Umbilical Cord Blood Transplantation for Hematologic Diseases in Patients Older than Fifty Years: A Eurocord-Center for International.

Bone Marrow Transplantation for Diamond-Blackfan Anemia

Yoshihiro Inamoto, Mary E. D

NCI, NHLBI/PBMTC First International Conference on Late Effects After Pediatric Hematopoietic Cell Transplantation: Persistent Immune Deficiency in Pediatric.

Sabina Kersting, Leo F. Verdonck

A Meta-Analysis of Unrelated Donor Umbilical Cord Blood Transplantation versus Unrelated Donor Bone Marrow Transplantation in Adult and Pediatric Patients

Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved Survival Mary.

Effect of Antithymocyte Globulin Source on Outcomes of HLA-Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Severe.

Stephanie J. Lee, Loretta A. Williams

Re: Twenty-Year Follow-Up in Patients with Aplastic Anemia Given Marrow Grafts from HLA-Identical Siblings and Randomized to Receive Methotrexate/Cyclosporine.

Recent Decrease in Acute Graft-versus-Host Disease in Children with Leukemia Receiving Unrelated Donor Bone Marrow Transplants Stella M. Davies, Dan.

J. J. Nietfeld, Marcelo C. Pasquini, Brent R

Jennifer Crombie, Laura Spring, Shuli Li, Robert J. Soiffer, Joseph H

Stem Cell Transplant for Children with Sickle Cell Anemia: Parent and Patient Interest Michael Roth, Julie Krystal, Deepa Manwani, Catherine Driscoll,

Bacteremia in Blood or Marrow Transplantation Patients: Clinical Risk Factors for Infection and Emerging Antibiotic Resistance Allison M. Bock, Qing.

Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic Transplantation Philippe Armand, Haesook T. Kim, Daniel.

Twenty Years of Unrelated Donor Bone Marrow Transplantation for Pediatric Acute Leukemia Facilitated by the National Marrow Donor Program Margaret L.

Evaluating the Impact of Antithymocyte Globulin on Lung Function at 1 Year after Allogeneic Stem Cell Transplantation Filippo Milano, Margaret A. Au,

Should Methotrexate plus Calcineurin Inhibitors Be Considered Standard of Care for Prophylaxis of acute Graft-versus-Host Disease? Rainer Storb, Joseph.

Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Adam.

Multicenter Biologic Assignment Trial Comparing Reduced-Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive.

A Randomized Trial of One versus Two Doses of Influenza Vaccine after Allogeneic Transplantation Nicole A. Karras, Matthew Weeres, Wendy Sessions, Xiyan.

Hematopoietic Cell Transplantation as Curative Therapy for Idiopathic Myelofibrosis, Advanced Polycythemia Vera, and Essential Thrombocythemia Daniella.

Cell-Based Therapy Using Umbilical Cord Blood for Novel Indications in Regenerative Therapy and Immune Modulation: An Updated Systematic Scoping Review.

Kasiani C. Myers, Stella M. Davies

Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation Betul Oran, John E. Wagner, Todd.

Relationship of CMV Reactivation and Rabbit Antithymocyte Globulin Administration in Allogeneic Stem Cell Transplant Patients LeAnne Kennedy, Marie Cavalier,

Cutaneous Complications in Hematopoietic Cell Transplant Recipients: Impact of Biopsy on Patient Management Oana Paun, Tycel Phillips, Pingfu Fu, Roberto.

Transplantation Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents with Acute Lymphoblastic.

Post-Transplant Cyclophosphamide as Sole Graft-versus-Host Disease Prophylaxis Is Feasible in Patients Undergoing Peripheral Blood Stem Cell Transplantation.

Frederick R. Appelbaum, Claudio Anasetti, Joseph H

Graft-versus-Host Disease Induced Graft-versus-Leukemia Effect: Greater Impact on Relapse and Disease-Free Survival after Reduced Intensity Conditioning

Thymoglobulin Prevents Chronic Graft-versus-Host Disease, Chronic Lung Dysfunction, and Late Transplant-Related Mortality: Long-Term Follow-Up of a Randomized.

Hematopoietic Cell Transplantation for Children with Acute Lymphoblastic Leukemia in Second Complete Remission: Similar Outcomes in Recipients of Unrelated.

Allogeneic Stem Cell Transplantation for Aplastic Anemia

Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation Rachel B. Salit, Filippo.

HLA-Mismatched, Noninherited Maternal Antigen–Matched Unrelated Cord Blood Transplantations Have Superior Survival: How HLA Typing the Cord Blood Donor's.

Pauline Damien, David S. Allan

Guidance for Developing Phase II Cell Therapy Trial Proposals for Consideration by the Blood and Marrow Transplant Clinical Trials Network Edwin M. Horwitz,

Pretransplantation Therapy with Azacitidine vs Induction Chemotherapy and Posttransplantation Outcome in Patients with MDS Aaron T. Gerds, Ted A. Gooley,

What is quality in a transplant program?

Issues of Aging and Geriatric Medicine: Relevance to Cancer Treatment and Hematopoietic Reconstitution William B. Ershler, Andrew S. Artz, Evan T. Keller

Chronic Graft-Versus-Host Disease (cGVHD) following Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT): Higher Response Rate In Recipients.

Richard Mitchell, John E. Wagner, Claudio Brunstein, Qing Cao, David H

Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews Emily C. Merkel, Sandra A. Mitchell,

Risk Factors Affecting Outcome of Second HLA-Matched Sibling Donor Transplantations for Graft Failure in Severe Acquired Aplastic Anemia John T. Horan,

Aplastic Anemia: Pathophysiology and Treatment

HLA-Allele Matched Unrelated Donors Compared to HLA-Matched Sibling Donors: Role of Cell Source and Disease Risk Category Ann Woolfrey, Stephanie J.

Unrelated Donor Hematopoietic Cell Transplantation: Factors Associated with a Better HLA Match Jason Dehn, Mukta Arora, Stephen Spellman, Michelle Setterholm,

Blood and Marrow Transplant Handbook

Young Female Donors Do Not Increase the Risk of Graft-versus-Host Disease or Impact Overall Outcomes in Pediatric HLA-Matched Sibling Hematopoietic Stem.

Preengraftment Syndrome after Unrelated Cord Blood Transplant Is a Strong Predictor of Acute and Chronic Graft-versus-Host Disease Haydar Frangoul, Li.

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter.

Mammen Chandy Biology of Blood and Marrow Transplantation

Twenty-Year Follow-Up of a Controlled Trial Comparing a Combination of Methotrexate Plus Cyclosporine with Cyclosporine Alone for Prophylaxis of Graft-versus-Host.

Treatment versus Transplant for Challenging Hematologic Disorders

Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin’s Lymphoma Ivan Aksentijevich,

Transplantation of Unrelated Donor Umbilical Cord Blood for Nonmalignant Diseases: a Single Institution's Experience with 45 Patients Tang-Her Jaing,

Mismatched Related and Unrelated Donors for Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancies Mary Eapen, Paul O'Donnell,

Mary Eapen Biology of Blood and Marrow Transplantation

How I treat acquired aplastic anemia

Claudio G. Brunstein, David H. McKenna, Todd E

Presentation transcript:

Optimization of Therapy for Severe Aplastic Anemia Based on Clinical, Biologic, and Treatment Response Parameters: Conclusions of an International Working Group on Severe Aplastic Anemia Convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010 Michael A. Pulsipher, Neal S. Young, Jakub Tolar, Antonio M. Risitano, H. Joachim Deeg, Paolo Anderlini, Rodrigo Calado, Seiji Kojima, Mary Eapen, Richard Harris, Phillip Scheinberg, Sharon Savage, Jaroslaw P. Maciejewski, Ramon V. Tiu, Nancy DiFronzo, Mary M. Horowitz, Joseph H. Antin Biology of Blood and Marrow Transplantation Volume 17, Issue 3, Pages 291-299 (March 2011) DOI: 10.1016/j.bbmt.2010.10.028 Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Treatment of acquired severe aplastic anemia according to United Kingdom Guidelines [13]. ATG, antithymocyte globulin; CSA, cyclosporine; FBC, full blood count (or CBC); MUD, matched unrelated donor; CRP, clinical research protocol; IST, immunosuppressive therapy; UCB, umbilical cord blood. Biology of Blood and Marrow Transplantation 2011 17, 291-299DOI: (10.1016/j.bbmt.2010.10.028) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Probability of survival in patients treated with IST who had high versus low absolute reticulocyte counts (ARC) and high versus low absolute lymphocyte counts (ALC). Patients undergoing BMT were censored at the time of transplant [27]. Biology of Blood and Marrow Transplantation 2011 17, 291-299DOI: (10.1016/j.bbmt.2010.10.028) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Survival among patients with severe aplastic anemia treated with ATG-based immunosuppression reported to the EBMT database (n = 2400) [36]. Biology of Blood and Marrow Transplantation 2011 17, 291-299DOI: (10.1016/j.bbmt.2010.10.028) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 Outcomes of URD BMT for SAA using fludarabine/cyclophosphamide/ATG ± low dose TBI reported to the EBMT. (A) Survival after Flu/Cy/ATG with TBI (median age 27 (7-53 years) versus Flu/Cy/ATG (median age 13 [3-51 years]). (B) Survival of patients transplanted ≤2 years from diagnosis versus those receiving transplantation later in their disease course. (C) Survival of patients transplanted in the most recent era (after 2004 versus those transplanted earlier) [11]. Biology of Blood and Marrow Transplantation 2011 17, 291-299DOI: (10.1016/j.bbmt.2010.10.028) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions